Psilocybin
My Stack

I. Abstract

Fungal-derived psychedelic prodrug used to stress-test controlled substances, active metabolite relationships, and serotonergic target specificity.

II. Activity Profile

Effects

documented physiological and clinical outcomes, ranked by evidence strength and magnitude

Altered PerceptionDRUGS

Altered Perception is indexed as a partial Psilocybin effect from the compound directory seed.

Evidence: Not Assessed·Magnitude: Not Assessed
Mood FlexibilityDRUGS

Mood Flexibility is indexed as a partial Psilocybin effect from the compound directory seed.

Evidence: Not Assessed·Magnitude: Not Assessed
NeuroplasticityDRUGS

Neuroplasticity is indexed as a partial Psilocybin effect from the compound directory seed.

Evidence: Not Assessed·Magnitude: Not Assessed

III. Dose Evidence

Target Range
protocol-specific
Frequency
protocol-specific
Timing
supervised setting
Clinical Notes

Controlled-substance entry; dosing is intentionally not generalized.

Exogenous prodrug exposure

Psilocybin is fungal-derived and not endogenously synthesized. It is converted to psilocin, the active serotonergic metabolite.

VI. Key Studies

Curated source records that explain the evidence landscape for this compound, including endpoint evidence, mechanism anchors, dose context, safety context, and limiting evidence.